358 related articles for article (PubMed ID: 28188239)
1. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
[TBL] [Abstract][Full Text] [Related]
4. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.
Herrick AL; Lunt M; Whidby N; Ennis H; Silman A; McHugh N; Denton CP
J Rheumatol; 2010 Jan; 37(1):116-24. PubMed ID: 19955050
[TBL] [Abstract][Full Text] [Related]
5. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
Mendoza FA; Lee-Ching C; Jimenez SA
Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
[TBL] [Abstract][Full Text] [Related]
6. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
7. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
Le EN; Wigley FM; Shah AA; Boin F; Hummers LK
Ann Rheum Dis; 2011 Jun; 70(6):1104-7. PubMed ID: 21378404
[TBL] [Abstract][Full Text] [Related]
8. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
Nihtyanova SI; Brough GM; Black CM; Denton CP
Rheumatology (Oxford); 2007 Mar; 46(3):442-5. PubMed ID: 16899504
[TBL] [Abstract][Full Text] [Related]
10. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.
Herrick AL; Peytrignet S; Lunt M; Pan X; Hesselstrand R; Mouthon L; Silman AJ; Dinsdale G; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk MC; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jobanputra P; Jordan AC; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov NS; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman SM; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2018 Apr; 77(4):563-570. PubMed ID: 29306872
[TBL] [Abstract][Full Text] [Related]
11. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
Mendoza FA; Nagle SJ; Lee JB; Jimenez SA
J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
[TBL] [Abstract][Full Text] [Related]
12. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
13. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
Derk CT; Grace E; Shenin M; Naik M; Schulz S; Xiong W
Rheumatology (Oxford); 2009 Dec; 48(12):1595-9. PubMed ID: 19846575
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.
Poelman CL; Hummers LK; Wigley FM; Anderson C; Boin F; Shah AA
J Rheumatol; 2015 Feb; 42(2):236-42. PubMed ID: 25433527
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.
Clark KEN; Campochiaro C; Csomor E; Taylor A; Nevin K; Galwey N; Morse MA; Singh J; Teo YV; Ong VH; Derrett-Smith E; Wisniacki N; Flint SM; Denton CP
Ann Rheum Dis; 2021 Dec; 80(12):1584-1593. PubMed ID: 34230031
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort.
Windirsch K; Jordan S; Becker MO; Bruni C; Dobrota R; Elhai M; Garaiman IA; Mihai CM; Iudici M; Hasler P; Ribi C; Maurer B; Gabrielli A; Hoffmann-Vold AM; Distler O
Swiss Med Wkly; 2024 Feb; 154():3630. PubMed ID: 38579324
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of combined glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis for skin sclerosis in diffuse systemic sclerosis.
Suga K; Yamashita H; Takahashi Y; Katagiri D; Hinoshita F; Kaneko H
Medicine (Baltimore); 2020 Mar; 99(10):e19301. PubMed ID: 32150064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
